Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Bharathi, Anekella"'
Autor:
Dana Ruminski Lowe, Benedicta Forson, Maria Cowen, Matthew G. Butler, Yves Konigshofer, Melissa Berenger, Krystyna Nahlik, Dianren Xia, Catherine Huang, Russell Garlick, Bharathi Anekella
Publikováno v:
Cancer Research. 83:6109-6109
Mutations in the tumor suppressor BRCA1 and BRCA2 genes can cause cell damage that significantly increases the risk of developing breast, ovarian, prostate, and pancreatic cancers. Large genomic rearrangements (LGRs) are defined as deletions, duplica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::242a4751de8553b7dc6523354ea98353
https://doi.org/10.1158/1538-7445.am2023-6109
https://doi.org/10.1158/1538-7445.am2023-6109
Abstract 6110: Multi-site evaluation of FFPE homologous recombination deficiency reference materials
Autor:
Dana Ruminski Lowe, Robert M. Whiting, Matthew G. Butler, Yves Konigshofer, Catherine Huang, Indira Chivukula, Krystyna Nahlik, Dianren Xia, Russell Garlick, Bharathi Anekella
Publikováno v:
Cancer Research. 83:6110-6110
Homologous recombination deficiency (HRD) arises when defects in DNA repair pathways occur, leading to genomic instability. HRD status is an emerging therapeutic biomarker; NGS assays that measure it can be used to stratify ovarian and breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::589e10b4db7361aa9bc6504926b4b2ff
https://doi.org/10.1158/1538-7445.am2023-6110
https://doi.org/10.1158/1538-7445.am2023-6110
Autor:
Tonya N. Watkins, Benedicta Forson, Dana Ruminski Lowe, Yves Konigshofer, Catherine Huang, Omoshile Clement, Bharathi Anekella
Publikováno v:
Cancer Research. 82:756-756
Next Generation Sequencing (NGS) is an important technology to identify genetic changes involved in lymphoid malignancies. Genome-level understanding of these changes can aid in diagnosis, prognosis, and therapy selection. Cancer biopsies are often p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c23783df870463b7649b601365afbc3d
https://doi.org/10.1158/1538-7445.am2022-756
https://doi.org/10.1158/1538-7445.am2022-756
Autor:
Dana Ruminski Lowe, Benedicta Forson, Matthew G. Butler, Yves Konigshofer, Catherine Huang, Omoshile Clement, Russell K. Garlick, Bharathi Anekella
Publikováno v:
Cancer Research. 82:537-537
TMB is a biomarker with potential for predicting positive patient response to immune checkpoint inhibitors. TMB measurements can be determined using genomic DNA extracted from FFPE-preserved tissue biopsy samples. However, assessment of TMB from a li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beb3396e92f56ad072a11fda86ba3a4d
https://doi.org/10.1158/1538-7445.am2022-537
https://doi.org/10.1158/1538-7445.am2022-537
Autor:
Dana Ruminski Lowe, Benedicta Forson, Matthew G. Butler, Yves Konigshofer, Catherine Huang, Omoshile Clement, Russell K. Garlick, Bharathi Anekella
Publikováno v:
Cancer Research. 82:2219-2219
Monitoring measurable residual disease (MRD) via liquid biopsy is a promising method for catching early stage cancer and disease relapse long before traditional diagnostics, which generally require significant disease progression for detection. Assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e23cf666b6baff1dbed99a20ab0ecb86
https://doi.org/10.1158/1538-7445.am2022-2219
https://doi.org/10.1158/1538-7445.am2022-2219
Autor:
Javier Martin, David W. Ussery, Tom Morrison, Siemon H. S. Ng, Jim F. Huggett, Michael Brewer, Serge Monpoeho, Heather Couch, Bharathi Anekella, Scott A. Jackson, Megan H. Cleveland, Pei-Ju Chin, Eric Delwart, Arifa S. Khan
Publikováno v:
Biologicals
Adventitious virus testing assures product safety by demonstrating the absence of viruses that may have been unintentionally introduced during the manufacturing process. The capabilities of next-generation sequencing (NGS) for broad virus detection i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9678a548649660fb1732684845e86df5
https://europepmc.org/articles/PMC9987593/
https://europepmc.org/articles/PMC9987593/
Publikováno v:
Cancer Research. 81:471-471
Immune Checkpoint Inhibitor (ICI) therapies continue to revolutionize treatment of advanced malignancies. However, identification of individuals who respond to ICI treatment remains challenging. Along with programmed death ligand 1(PD-L1 aka CD274) e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecc4314901d9886f39e472e795794de2
https://doi.org/10.1158/1538-7445.am2021-471
https://doi.org/10.1158/1538-7445.am2021-471
Autor:
Jessica Dickens, Rajeswari Vemula, Matthew G. Butler, Catherine Huang, Bharathi Anekella, Omoshile Clement, Yves Konigshofer
Publikováno v:
Cancer Research. 81:2232-2232
Purpose: Whole transcriptome RNA-sequencing (RNA-Seq) has emerged as one of the most effective methods for detection of genomic rearrangements in cancer. Enrichment for poly(A) + RNA as part of library preparation is a standard method to select for m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fa964ca0c93fd9e8c9ee43c933c31ad
https://doi.org/10.1158/1538-7445.am2021-2232
https://doi.org/10.1158/1538-7445.am2021-2232
Autor:
Bharathi Anekella, Elizabeth Hynes, Catherine Huang, Emily M. Kudalkar, Russell K. Garlick, Birgit Funke, Mark Bowser, Naif A.M. Almontashiri
Publikováno v:
The Journal of Molecular Diagnostics. 18:882-889
Diagnostic next-generation sequencing (NGS)-based gene panels are increasingly used for prevalent disorders with genetic and clinical heterogeneity. Clinical development, validation, and quality management of these panels ideally includes reference s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bc02e709e3e3a4d9b741ea85df0a269
https://doi.org/10.1016/j.jmoldx.2016.07.005
https://doi.org/10.1016/j.jmoldx.2016.07.005
Autor:
Omoshile Clement, Andrew Anfora, Bharathi Anekella, Russell Garlick, Dan Brudzewsky, Yves Konigshofer, Matthew G. Butler
Publikováno v:
Cancer Research. 80:1982-1982
Tumor mutational burden (TMB) is a measurement of the somatic mutations acquired by a tumor genome that cause nonsynonymous changes in proteins. TMB is a biomarker that serves as a proxy for the potential to produce neoantigens that will be recognize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f663a665ff792a9c0bc9525483b6d2cc
https://doi.org/10.1158/1538-7445.am2020-1982
https://doi.org/10.1158/1538-7445.am2020-1982